Analisis Keuangan Saham BPTH - Bio-Path Holdings, Inc. (OTCPK) Stock

Bio-Path Holdings, Inc.
US ˙ OTCPK

Gambaran Umum
Bio-Path Holdings, Inc., headquartered in the United States, operates within the biotechnology sector, focusing primarily on the development of RNAi (RNA interference) therapeutics that inhibit enzymes or proteins where there are clear paths to efficacy. As a clinical-stage company, their key efforts center on treatments for hematologic malignancies and solid tumors. Notably, Bio-Path is advancing a portfolio of nucleic acid cancer drugs with its proprietary DNAbilize® technology—a lipid nanoparticle delivery system. Major projects include preclinical and clinical trials targeting acute myeloid leukemia and chronic myeloid leukemia, among other cancers, deploying strategies that facilitate systemic administration with minimal toxicities, thereby aiming to improve patient outcomes in cancer care.
Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
  • Nilai operating income untuk Bio-Path Holdings, Inc. per 2025 Jun 30 adalah -13.06 MM.
  • Nilai net income untuk Bio-Path Holdings, Inc. per 2025 Jun 30 adalah -12.32 MM.
Period End (TTM) Revenue (MM) Operating Income (MM) Net Income (MM)
2025-06-30 -13.06 -12.32
2025-03-31 -11.54 -9.59
2024-12-31 -11.99 -9.89
2024-09-30 -12.40 -10.51
2024-06-30 -13.04 -11.60
2024-03-31 -14.25 -13.96
2023-12-31 -15.84 -16.08
2023-09-30 -16.80 -16.67
2023-06-30 -17.07 -17.01
2023-03-31 -15.83 -15.78
2022-12-31 -13.90 -13.87
2022-09-30 -14.03 -14.02
2022-06-30 -12.55 -12.55
2022-03-31 -11.35 -11.35
2021-12-31 -10.44 -10.44
2021-09-30 -8.88 -8.87
2021-06-30 -9.78 -9.77
2021-03-31 -10.01 -10.01
2020-12-31 -10.91 -10.88
2020-09-30 -10.77 -10.72
Laporan Laba Rugi: EPS
  • earnings per share basic untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -2.17.
  • laba per saham yang terdilusi untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -2.17.
Period End (TTM) Earnings Per Share Basic Earnings Per Share Diluted
2025-06-30 -2.17 -2.17
2025-03-31 -2.39 -2.39
2024-12-31 -4.12
2024-09-30 -7.13 -7.12
2024-06-30 -13.74 -13.74
2024-03-31 -25.84 -25.84
2023-12-31 -33.64
2023-09-30 -39.67 -39.69
2023-06-30 -44.29 -44.30
2023-03-31 -42.20 -42.20
2022-12-31 -38.10 -38.12
2022-09-30 -39.15 -39.15
2022-06-30 -35.19 -35.21
2022-03-31 -32.05 -32.06
2021-12-31 -31.05
2021-09-30 -29.52 -29.52
2021-06-30 -37.78 -37.78
2021-03-31 -45.95 -45.95
2020-12-31 -56.57
2020-09-30 -60.02 -60.02
Arus Kas: Operasi, Investasi, Pendanaan
  • Nilai cash from operating activities untuk Bio-Path Holdings, Inc. per 2025 Jun 30 adalah -7.91 MM.
  • Nilai kas dari aktivitas pendanaan untuk Bio-Path Holdings, Inc. per 2025 Jun 30 adalah 3.90 MM.
Period End (TTM) Cash From Operating Activities (MM) Cash From Investing Activities (MM) Cash From Financing Activities (MM)
2025-06-30 -7.91 3.90
2025-03-31 -10.85 10.78
2024-12-31 -10.57 10.70
2024-09-30 -9.51 7.72
2024-06-30 -8.86 9.42
2024-03-31 -8.92 2.38
2023-12-31 -11.54 2.20
2023-09-30 -14.72 0.00 3.42
2023-06-30 -15.31 0.00 1.73
2023-03-31 -16.23 -0.02 1.73
2022-12-31 -15.10 -0.02 1.73
2022-09-30 -12.90 -0.04 -0.00
2022-06-30 -12.42 -0.04 1.40
2022-03-31 -10.87 -0.07 1.40
2021-12-31 -9.92 -0.07 20.01
2021-09-30 -9.71 -0.05 24.30
2021-06-30 -9.17 -0.05 22.90
2021-03-31 -10.00 22.90
2020-12-31 -10.96 4.29
2020-09-30 -10.61 7.29
Metrik Penilaian: PE, PriceToBook, PriceToTBV
  • p/e untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -0.18.
  • p/libro untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -0.67.
  • p/tbv untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -0.67.
P/Book
The current closing price divided by the book value per share.
P/TBV
The current price divided by the tangible book value per share.
Period End (TTM) p/e P/Book P/TBV
2025-06-30 -0.18 -0.67 -0.67
2025-03-31 -0.09 5.87 5.87
2024-12-31 -7.08 -7.08
2024-09-30 -0.20 1.83 1.83
2024-06-30 -0.26 -1.36 -1.36
2024-03-31 -0.17 6.22 6.22
2023-12-31 -0.35 2.33 2.33
2023-09-30 -0.25 0.84 0.84
2023-06-30 -0.89 1.54 1.54
2023-03-31 -0.80 0.78
2022-12-31 0.74 0.74
2022-09-30 1.19 1.19
2022-06-30 -2.43 1.24 1.24
2022-03-31 -2.62 1.07 1.07
2021-12-31 -3.05 0.92 0.92
2021-09-30 -3.67 1.20 1.20
2021-06-30
2021-03-31 -2.01 0.64 0.64
2020-12-31 -1.21 0.87 0.87
2020-09-30 -1.00 0.81 0.81
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
  • EBIT/EV untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -5.91.
  • EBIT (3 tahun) / EV untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -7.85.
Period End (TTM) EBIT/EV EBIT (3y)/EV
2025-06-30 -5.91 -7.85
2025-03-31 36.84 49.20
2024-12-31 -2.35 -3.01
2024-09-30 7.08 8.60
2024-06-30 -4.12 -4.04
2024-03-31 -9.51 -7.96
2023-12-31 -4.73 -3.74
2023-09-30 -21.36 -16.47
2023-06-30 -2.17 -1.75
2023-03-31 -20.40 -17.27
2022-12-31 8.20 6.55
2022-09-30 -2.03 -1.74
2022-06-30 -1.80 -1.64
2022-03-31 -2.92 -2.87
2021-12-31 -19.11 -20.35
2021-09-30 -1.26 -1.23
2021-06-30
2021-03-31 0.94 0.89
2020-12-31 17.30 14.87
2020-09-30 7.72 6.65
Efektivitas Manajemen
  • roa untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -1.87.
  • roe untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -7.43.
Period End (TTM) ROA ROE ROIC (Tingkat Pengembalian Investasi Modal) CROIC OCROIC
2025-06-30 -1.87 -7.43
2025-03-31 -5.60 -41.75 0.51 -44.62
2024-12-31 -3.26 -23.84
2024-09-30 -2.31 -4.59 -8.60 0.42 -6.57
2024-06-30 -1.26 -1.53
2024-03-31 -1.01 -1.13 -29.02 -16.84 -20.82
2023-12-31 -0.90 -1.03 -6.25 -4.24 -5.52
2023-09-30 -0.81 -0.87 -3.26 -2.61 -2.94
2023-06-30 -0.75 -0.81 -3.26 -2.61 -2.94
2023-03-31 -0.58 -0.62 -1.70 -1.56 -1.74
2022-12-31 -0.46 -0.48 -0.85 -0.79 -0.78
2022-09-30 -0.41 -0.43 -0.85 -0.79 -0.78
2022-06-30 -0.36 -0.38 -0.63 -0.56 -0.63
2022-03-31 -0.32 -0.33 -0.50 -0.42 -0.48
2021-12-31 -0.54 -0.59 -0.41 0.39 -0.33
2021-09-30 -0.60 -0.74 -0.30 0.49 -0.31
2021-06-30 -0.56 -0.61 -0.33 0.46 -0.31
2021-03-31 -0.50 -0.56 -0.32 0.41 -0.32
2020-12-31 -0.48 -0.52 -0.71 -0.43 -0.71
2020-09-30 -0.61 -0.67 -0.79 -0.25 -0.78
Gross Margins
Margin Kotor
The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
Margin Keuntungan Bersih
Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
Margin Operasi
Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) Margin Kotor Margin Keuntungan Bersih Margin Operasi
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK)1133818
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations
Other Listings
DE:IBP0
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista